Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Adeline Valentine"'
Publikováno v:
Current Microbiology. 23:271-276
Proteus mirabilis can grow anaerobically on the fermentable substrate, glucose. When the glucose medium was supplemented with an electron acceptor, growth doubled. However, the organism failed to grow anaerobically on the oxidizable substrate glycero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1eb31ab75269714a29670f19f5016c2
https://doi.org/10.1007/bf02092029
https://doi.org/10.1007/bf02092029
Autor:
Sharon Walmsley, Daniel R. Kuritzkes, Ralph DeMasi, Christine Katlama, Mark T. Nelson, Jacques Reynes, Adeline Valentine, Jain Chung, Hans-Jürgen Stellbrink, David A. Cooper, Denise Guimaraes, Joep M. A. Lange, Joseph J. Eron, Adriano Lazzarin, Calvin J. Cohen, Keikawus Arastéh, Lucille Donatacci, Neil Buss, Bonaventura Clotet, Martin Wilkinson, Jean-François Delfraissy, Julio S. G. Montaner, Jacob Lalezari, Lucy Rowell, Miklos Salgo, Benoit Trottier, Mary O' Hearn, Keith Henry
Publikováno v:
AIDS patient care and STDs, 21(8), 533-543. Mary Ann Liebert Inc.
The additional 48-week optional treatment extension of the T-20 versus Optimized Regimen Only (TORO) studies evaluated long-term safety and efficacy of enfuvirtide (ENF) through week 96 in patients receiving ENF plus optimized background (OB) and pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea144cd6110d17ab7fae7b1aee8c58e
https://pure.amc.nl/en/publications/toro-ninetysixweek-virologic-and-immunologic-response-and-safety-evaluation-of-enfuvirtide-with-an-optimized-background-of-antiretrovirals(5d441686-f66b-4f8c-9a87-5b58aae6da30).html
https://pure.amc.nl/en/publications/toro-ninetysixweek-virologic-and-immunologic-response-and-safety-evaluation-of-enfuvirtide-with-an-optimized-background-of-antiretrovirals(5d441686-f66b-4f8c-9a87-5b58aae6da30).html
Autor:
Joep M. A. Lange, Jean François Delfraissy, Adriano Lazzarin, Lucille Donatacci, Keith Henry, Neil Buss, Martin Wilkinson, Bonaventura Clotet, David A. Cooper, Mary O'Hearn, Jacob Lalezari, Mark T. Nelson, Julio S. G. Montaner, Jain Chung, Jacques Reynes, Hans Jürgen Stellbrink, Daniel R. Kuritzkes, Miklos Salgo, Adeline Valentine, Peter J. Piliero, Sharon Walmsley, Calvin Cohen, Christine Katlama, Cynthia Wat, Lynn Smiley, Joseph J. Eron, Denise Guimaraes, Benoit Trottier, Keikawus Arastéh, Ralph DeMasi
Publikováno v:
Journal of acquired immune deficiency syndromes (1999), 40(4), 404-412. Lippincott Williams and Wilkins
BACKGROUND The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2 clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing enfuvirtide plus an optimized background (OB) of antiretrovirals (n = 661) with OB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e00bcc88e61ef05ead623d3f1fa1873
https://pure.amc.nl/en/publications/durable-efficacy-of-enfuvirtide-over-48-weeks-in-heavily-treatmentexperienced-hiv1infected-patients-in-the-t20-versus-optimized-background-regimen-only-1-and-2-clinical-trials(4eb2f353-46e3-4061-84af-7df5191c9cad).html
https://pure.amc.nl/en/publications/durable-efficacy-of-enfuvirtide-over-48-weeks-in-heavily-treatmentexperienced-hiv1infected-patients-in-the-t20-versus-optimized-background-regimen-only-1-and-2-clinical-trials(4eb2f353-46e3-4061-84af-7df5191c9cad).html